BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10483820)

  • 1. Resource implications of febrile neutropenia in cancer patients. An international collaborative study.
    Harbarth S; Beeler I; Viot M; Szucs TD
    Support Care Cancer; 1999 Sep; 7(5):343-6. PubMed ID: 10483820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital.
    Osmani AH; Ansari TZ; Masood N; Ahmed B
    Asian Pac J Cancer Prev; 2012; 13(6):2523-6. PubMed ID: 22938399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in antimicrobial utilization for febrile neutropenia in cancer patients. The CEMIC Study Group. Club d'Etudes des Maladies Infectieuses en Cancer.
    Harbarth S; Viot M; Beeler I; Klastersky J; Szucs T;
    Infection; 2000; 28(6):375-8. PubMed ID: 11139157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
    Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
    J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
    Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
    Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.
    Castagnola E; Fontana V; Caviglia I; Caruso S; Faraci M; Fioredda F; Garrè ML; Moroni C; Conte M; Losurdo G; Scuderi F; Bandettini R; Tomà P; Viscoli C; Haupt R
    Clin Infect Dis; 2007 Nov; 45(10):1296-304. PubMed ID: 17968824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective audit of treatment of paediatric febrile neutropenia in Australasia.
    Chamberlain JD; Smibert E; Skeen J; Alvaro F
    J Paediatr Child Health; 2005 Nov; 41(11):598-603. PubMed ID: 16398846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
    Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas.
    Costa VC; Ferraz MB; Petrilli AS; Pereira CA; Rogerio JW
    Support Care Cancer; 2003 Jun; 11(6):356-61. PubMed ID: 12720070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
    Van de Wyngaert Z; Berthon C; Debarri H; Bories C; Bonnet S; Nudel M; Carpentier B; Legrand C; Barbieux S; Chauvet P; Simonnet A; Willaume A; Bossard JB; Renaud L; Wattebled KJ; Escure G; Branche N; Arib I; Titecat M; Quesnel B; Alfandari S
    Int J Antimicrob Agents; 2019 Jun; 53(6):781-788. PubMed ID: 30831232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
    Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
    J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcome of febrile neutropenic episodes in paediatric oncology at the Wendy Fitzwilliam Paediatric Hospital.
    Timothy M; Bodkyn C
    West Indian Med J; 2011 Mar; 60(2):153-7. PubMed ID: 21942119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.